|1.||Neiger, R: 9 articles (01/2014 - 06/2002)|
|2.||Ramsey, I K: 7 articles (03/2011 - 09/2005)|
|3.||Reusch, C E: 6 articles (10/2013 - 07/2006)|
|4.||Sieber-Ruckstuhl, N S: 5 articles (10/2013 - 07/2006)|
|5.||Boretti, F S: 5 articles (10/2013 - 07/2006)|
|6.||Tebb, A J: 5 articles (03/2011 - 11/2005)|
|7.||Arenas, C: 3 articles (03/2014 - 12/2007)|
|8.||Melián, C: 3 articles (03/2014 - 12/2007)|
|9.||Pérez-Alenza, M D: 3 articles (03/2014 - 12/2007)|
|10.||Ramsey, I: 3 articles (01/2012 - 06/2002)|
|1.||Adrenocortical Hyperfunction (Adrenal Gland Hyperfunction)
02/01/2012 - "Recently, trilostane has been proven to be an effective treatment of pituitary-dependent hyperadrenocorticism and is approved for use in other countries. "
02/01/2007 - "Recently, trilostane has been proven to be an effective treatment of pituitary-dependent hyperadrenocorticism and is approved for use in other countries. "
01/01/2013 - "Efficacy of low- and high-dose trilostane treatment in dogs (< 5 kg) with pituitary-dependent hyperadrenocorticism."
03/01/2004 - "Trilostane ameliorates clinical signs of feline hyperadrenocorticism, but more research is needed before it can be recommended for treatment."
11/01/2013 - "To characterize the long-term efficacy of trilostane in treating cats with hyperadrenocorticism (HAC). "
01/01/1983 - "Although effective in some cases of Cushing's syndrome, the variability of the effect of trilostane may limit its usefulness as a therapeutic agent."
06/01/2003 - "Efficacy of trilostane for the treatment of equine Cushing's syndrome."
01/10/2015 - "Prognostic factors for survival in dogs with pituitary-dependent hypercortisolism treated with trilostane."
07/01/2013 - "Forty trilostane-treated dogs with pituitary-dependent hypercortisolism (PDH) were included in this prospective study. "
01/01/2010 - "The medical records of 63 dogs with pituitary-dependent hypercortisolism (PDH) before and during treatment with trilostane were reviewed retrospectively. "
|3.||Hyperaldosteronism (Conn Syndrome)
09/01/1986 - "These results suggest that trilostane is a safe, feasible therapeutic agent for long-term treatment of idiopathic hyperaldosteronism."
09/01/1986 - "Long-term treatment of idiopathic hyperaldosteronism using trilostane."
01/01/1985 - "Primary aldosteronism: treatment with trilostane."
11/19/1983 - "It is concluded from these results that trilostane is an effective therapeutic agent in primary aldosteronism, especially where there is no indication for surgery."
11/19/1983 - "[Therapy of primary aldosteronism with trilostane]."
|4.||Hypertension (High Blood Pressure)
02/01/2005 - "The intracerebroventricular, but not subcutaneous, infusion of 0.3 microg/h trilostane effectively blocked the increase in systolic blood pressure and reversed the hypertension produced by drinking 0.9% saline. "
02/01/2005 - "To test the hypothesis that de novo synthesis of aldosterone in the brain has a pathophysiological role in the salt-induced hypertension of the SS rat, the 3beta-steroid dehydrogenase antagonist trilostane was infused continuously intracerebroventricularly or subcutaneously in two different cohorts of Dahl SS/jr rats, one female, the other male, during and after the development of salt-induced hypertension. "
03/20/1982 - "It is concluded that trilostane is an effective inhibitor of 3-hydroxysteroid dehydrogenase in vivo and that it is useful in the treatment of primary aldosteronism and other hypertension due to hyperproduction of aldosterone."
01/10/2015 - "Clinical signs, liver enzymes, serum cortisol concentrations of the endocrine tests, proteinuria, systolic hypertension, the presence of concomitant disorders, and the frequency of trilostane administration were not associated with survival time. "
01/01/1983 - "(2 alpha, 4 alpha, 5 alpha, 17 beta)-4, 5-[Epoxy-17-hydroxy-3-oxo-androstane-2-carbonitrile (Trilostane, Win 24450) is a new, orally active, competitive inhibitor of 3 beta-hydroxysteroid dehydrogenase currently being introduced into therapy of Cushing's disease and primary aldosteronism and being investigated in the treatment of low-renin essential hypertension. "
11/19/1983 - "Trilostane was used for the treatment of 3 male and 2 female patients with primary aldosteronism, two of whom had an adenoma of the adrenal cortex and three bilateral adrenal hyperplasia. "
01/01/2011 - "Long-term efficacy of trilostane for Cushing's syndrome due to adrenocorticotropin-independent bilateral macronodular adrenocortical hyperplasia."
01/01/1985 - "Trilostane proved to be an effective inhibitor of aldosterone biosynthesis and was found useful in the treatment of primary aldosteronism both in patients with adrenal adenoma and in those with bilateral adrenal hyperplasia."
02/01/1985 - "The practicability and tolerability of trilostane, a competitive inhibitor of 3 beta-hydroxysteroid-delta 5-dehydrogenase, for the therapy of primary aldosteronism was assessed in 1 patient with aldosterone-producing adenoma (APA) and 3 subjects with idiopathic adrenal hyperplasia (IHA). "
01/01/1985 - "Trilostane, an inhibitor of the 3 beta-hydroxysteroid dehydrogenase enzyme system of steroid biosynthesis, was applied to 18 patients with primary aldosteronism (9 patients with adrenal adenoma, 9 patients with bilateral adrenal hyperplasia) for 12 weeks. "
|4.||3-Hydroxysteroid Dehydrogenases (3 beta Hydroxysteroid Dehydrogenase)
|5.||Adrenocorticotropic Hormone (ACTH)
|3.||Continuous Ambulatory Peritoneal Dialysis (CAPD)